Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14

Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non–small cell lung cancer (NSCLC) positive for skipping mutations of MET exon 14 (METex14). Drug‐induced interstitial lung disease (ILD) is a relatively rare, but potentially serious, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanemura, Hiroaki, Takeda, Masayuki, Shimizu, Shigeki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882388/
https://www.ncbi.nlm.nih.gov/pubmed/33347701
http://dx.doi.org/10.1111/1759-7714.13790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882388/
https://www.ncbi.nlm.nih.gov/pubmed/33347701
http://dx.doi.org/10.1111/1759-7714.13790

Ejemplares similares